Find Out if This New Medication Can Help Reduce Bronchiectasis Exacerbation
Research Centre: Respiratory Clinical Trials Unit, Royal Adelaide Hospital
Location: Corner of North Terrace and West Terrace Adelaide SA 5000
Lead Researcher: Dr Hugh Greville, Jenny McGrath and Louise Milazzo
Ethics Committee: This study has been reviewed and approved by the Royal Adelaide Hospital Human Research Ethics Committee
Bronchiectasis is a debilitating condition of the lungs characterised by chronic inflammation, thickening and dilation of the lung airways due to build-up of excess mucus. Individuals suffering from this condition often experience exacerbation symptoms including fatigue, severe cough, breathlessness, and thick sputum.
The Respiratory Clinical Trials Unit at the Royal Adelaide Hospital is conducting a study on a new treatment for bronchiectasis. The objective of the study is to find out if the new medication can lessen the frequency and duration of exacerbations.
This study seeks men and women who currently suffer from bronchiectasis. Participants are required to attend 7 study visits at the research site over 12 months.
- You may experience a reduction in the number of exacerbation episodes.
- You will be helping to advance medical research relating to bronchiectasis.
- You will get the investigational medication free of charge
- If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
- Your records relating to this study and any other information received will be kept strictly confidential, except as required by law.
- Qualified health professionals will monitor your health as it relates to the study.
Who Can Participate?
- Men and women aged 18+ who have been diagnosed with bronchiectasis.
- Able to attend 7 study visits at the research site over approximately 12 months.
- Has no history of cystic fibrosis.
- Has no other respiratory or pulmonary disease.